We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis AG (NVS - Free Report) , American Express Co. (AXP - Free Report) , ConocoPhillips (COP - Free Report) , Netflix, Inc. (NFLX - Free Report) and Schlumberger Ltd. (SLB - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Novartis, American Express & ConocoPhillips
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis AG, American Express Co. and ConocoPhillips. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Novartis have gained +2.3% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +16.2%. The company's efforts to restructure its business are encouraging. With the separation of Sandoz, it has become a pure-play pharmaceutical company.
Drugs like Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio continue to fuel growth and offset the impact of generic competition. The uptake of Pluvicto and Scemblix has been outstanding and should fuel top-line growth. The acquisition of Chinook Therapeutics has strengthened its renal pipeline.
However, generic competition for key drugs like Gilenya and pipeline setbacks are concerning. Earnings estimates for the first quarter are static ahead of the quarterly results.
American Express shares have outperformed the Zacks Financial - Miscellaneous Services industry over the past year (+44.1% vs. +17.1%). The company's growth initiatives, like launching new products, reaching new agreements and forging alliances, are boosting its revenues. Consumer spending on T&E, which carries higher margins for AmEx, is advancing well.
American Express' balance sheet looks strong with ample cash. Solid cash-generation abilities enable the pursuit of business investments and prudent deployment of capital via buybacks and dividends.
However, with higher utilization of the firm's cards, expenses in the form of card member services and card member rewards are likely to go up and strain its margins. Its current debt level amid a high-interest rate environment induces a rise in interest expenses. As such, the stock warrants a cautious stance.
Shares of ConocoPhillips have outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+27.8% vs. +20.3%). The company is poised for a robust oil and natural gas production outlook, benefiting from its extensive untapped drilling locations in cost-effective and diverse upstream assets such as Eagle Ford shale, Permian Basin and Bakken shale.
ConocoPhillips is strategically expanding its presence in the liquefied natural gas market to address the growing demands of energy transition toward a low-carbon future. Further, ConocoPhillips' minimal debt exposure provides resilience during periods of low commodity prices and enhances its capacity to increase dividends.
However, a significant reliance on crude exposes the exploration and production firm to oil price fluctuations. On the cost front, inflationary pressures may contribute to a significant increase in production and operating expenses in 2024, thereby squeezing margins.
Other noteworthy reports we are featuring today include Netflix, Inc. and Schlumberger Ltd..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
For Immediate Release
Chicago, IL – April 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis AG (NVS - Free Report) , American Express Co. (AXP - Free Report) , ConocoPhillips (COP - Free Report) , Netflix, Inc. (NFLX - Free Report) and Schlumberger Ltd. (SLB - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Novartis, American Express & ConocoPhillips
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis AG, American Express Co. and ConocoPhillips. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Novartis have gained +2.3% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +16.2%. The company's efforts to restructure its business are encouraging. With the separation of Sandoz, it has become a pure-play pharmaceutical company.
Drugs like Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio continue to fuel growth and offset the impact of generic competition. The uptake of Pluvicto and Scemblix has been outstanding and should fuel top-line growth. The acquisition of Chinook Therapeutics has strengthened its renal pipeline.
However, generic competition for key drugs like Gilenya and pipeline setbacks are concerning. Earnings estimates for the first quarter are static ahead of the quarterly results.
(You can read the full research report on Novartis here >>>)
American Express shares have outperformed the Zacks Financial - Miscellaneous Services industry over the past year (+44.1% vs. +17.1%). The company's growth initiatives, like launching new products, reaching new agreements and forging alliances, are boosting its revenues. Consumer spending on T&E, which carries higher margins for AmEx, is advancing well.
American Express' balance sheet looks strong with ample cash. Solid cash-generation abilities enable the pursuit of business investments and prudent deployment of capital via buybacks and dividends.
However, with higher utilization of the firm's cards, expenses in the form of card member services and card member rewards are likely to go up and strain its margins. Its current debt level amid a high-interest rate environment induces a rise in interest expenses. As such, the stock warrants a cautious stance.
(You can read the full research report on American Express here >>>)
Shares of ConocoPhillips have outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+27.8% vs. +20.3%). The company is poised for a robust oil and natural gas production outlook, benefiting from its extensive untapped drilling locations in cost-effective and diverse upstream assets such as Eagle Ford shale, Permian Basin and Bakken shale.
ConocoPhillips is strategically expanding its presence in the liquefied natural gas market to address the growing demands of energy transition toward a low-carbon future. Further, ConocoPhillips' minimal debt exposure provides resilience during periods of low commodity prices and enhances its capacity to increase dividends.
However, a significant reliance on crude exposes the exploration and production firm to oil price fluctuations. On the cost front, inflationary pressures may contribute to a significant increase in production and operating expenses in 2024, thereby squeezing margins.
(You can read the full research report on ConocoPhillips here >>>)
Other noteworthy reports we are featuring today include Netflix, Inc. and Schlumberger Ltd..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.